Fresh Tracks Therapeutics (NASDAQ:FRTX) Trading Down 1.1%

Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX)’s stock price fell 1.1% on Friday . The company traded as low as $0.91 and last traded at $0.91. 795 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 17,504 shares. The stock had previously closed at $0.92.

Fresh Tracks Therapeutics Stock Down 1.1 %

The stock’s 50 day moving average is $0.91 and its two-hundred day moving average is $0.91. The company has a market capitalization of $5.43 million, a PE ratio of -0.65 and a beta of 0.39.

Fresh Tracks Therapeutics (NASDAQ:FRTX) last released its quarterly earnings data on Friday, March 15th. The company reported ($0.20) earnings per share for the quarter. Fresh Tracks Therapeutics had a negative return on equity of 60.83% and a negative net margin of 91.29%.

Fresh Tracks Therapeutics Company Profile

Fresh Tracks Therapeutics, Inc, a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops FRTX-02 (BBI-02), an oral DYRK1A inhibitor that is completed Phase 1 clinical trials for the treatment of autoimmune and inflammatory diseases; FRTX-10 (BBI-10), a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases; and FRTX-03, a topical DYRK1A inhibitor for the treatment of mild-to-moderate skin conditions, as well as next-generation kinase inhibitors.